Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | PDE6A | P16499 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791300 | 0.92 | TLR7 (0.39) | HTTAGTR1AGTR2KMT2ASMN1; SMN2 | |
| SCHEMBL5338601 | 0.90 | BRD4 (0.41) | HTTKMT2ASMN1; SMN2BRD4MEN1 | |
| SCHEMBL4793922 | 0.88 | HTT (0.38) | HTTKMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4793540 | 0.84 | HTT (0.42) | HTTAGTR1AGTR2KMT2ASMN1; SMN2 | |
| SCHEMBL4791296 | 0.83 | HTT (0.36) | HTTKMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4794054 | 0.82 | CYP1A2 (0.44) | HTTKMT2ASMN1; SMN2MEN1TLR7 | |
| SCHEMBL5338594 | 0.82 | HTT (0.37) | HTTKMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL5337932 | 0.81 | TLR7 (0.35) | TLR7 | |
| SCHEMBL6286213 | 0.81 | HTT (0.46) | HTTAGTR1AGTR2KMT2ASMN1; SMN2 | |
| SCHEMBL4791724 | 0.81 | TP53 (0.47) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-09 | — | — | US | disclosed |
| US-7125890-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-6797718-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040010007-A1 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | IL2, IL4, MYD88 | HTT 4588/4885AGTR1 667/4885AGTR2 1220/4885 |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | IL2, IFNG, TSLP | HTT 4440/4885AGTR1 715/4885AGTR2 1792/4885 |
| US-20040010007-A1 | Ether substituted imidazopyridines | IL2, IL4, MYD88 | HTT 4588/4885AGTR1 667/4885AGTR2 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.